Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12200521 | 1.00 | IRAK4 (0.31) | IRAK4 | |
| SCHEMBL609051 | 0.83 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL609052 | 0.83 | IRAK4 (0.32) | IRAK4 | |
| SCHEMBL28668136 | 0.80 | — | — | |
| SCHEMBL2658028 | 0.79 | SIRT6 (0.40) | — | |
| Ammonia Solution, Strong SCHEMBL1062274 | 0.77 | TBXAS1 (0.31) | — | |
| SCHEMBL24708390 | 0.76 | NSD2 (0.31) | IRAK4 | |
| SCHEMBL30000758 | 0.76 | NSD2 (0.31) | IRAK4 | |
| SCHEMBL28667072 | 0.76 | PCSK9 (0.39) | — | |
| SCHEMBL972934 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2275414-B1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034819-B2 | Glucokinase activator | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | TEIJIN LIMITED (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | IRAK4 4533/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | IRAK4 4533/4885 |
| US-20100099671-A1 | GLUCOKINASE ACTIVATOR | GCK, GCKR, GALK1 | IRAK4 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.